Physician profile
John Morehead
NPI 1649267873
$896.42
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $263 · 2021: $410 · 2022: $15.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.92 | 2019-2021 | |
| Daiichi Sankyo INC. | $118.02 | 2019-2021 | |
| Novo Nordisk INC | $106.19 | 2021 | |
| Ethicon US, LLC | $69.07 | 2019-2021 | |
| Avion Pharmaceuticals | $49.18 | 2020 | |
| Pfizer INC. | $35.26 | 2021 | |
| Astellas Pharma US INC | $25.12 | 2021 | |
| Exeltis, USA INC. | $21.11 | 2020 | |
| Roche Diagnostics Corporation | $17.61 | 2019 | |
| Virtus Pharmaceuticals LLC | $17.45 | 2021 | |
| Organon LLC | $15.63 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.46 | 2020 | |
| Therapeuticsmd, INC. | $14.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.30 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.04 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $14.04 | 2021 | |
| Merck Sharp & Dohme LLC | $13.46 | 2019 | |
| Amgen INC. | $13.11 | 2020 | |
| Olympus America INC. | $12.78 | 2021 | |
| Boston Scientific Corporation | $12.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.